Not Yet Recruiting PHASE2/PHASE3 INTERVENTIONAL 1-arm
NCT06684184
Blinatumomab in Refractory Myasthenia Gravis (BLINA-MG) (BLINA-MG)
Safety and Efficacy of Blinatumomab in Refractory Myasthenia Gravis
Sponsor: Zhongming Qiu
Conditions
Myasthaenia Gravis
Interventions
Blinatumomab
Updated 1 time since 2024 Last updated: Nov 10, 2024 Started: Nov 30, 2024 Primary completion: Dec 31, 2025 Completion: Jun 30, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
A PHASE2/PHASE3 clinical study on Myasthaenia Gravis, this trial is actively recruiting participants. The trial is conducted by Zhongming Qiu and has accumulated 1 data snapshot since 2024. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
1 version recorded Not Yet Recruiting — PHASE2/PHASE3
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Zhongming Qiu
Data source: Xinqiao Hospital of Chongqing
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.